Abstract:Background: Much effort has been expended in exploring the connections between transcriptome, disease and drug, based on the premise that drug induced perturbations in the transcriptome will affect the phenotype and finally help to cure a disease. MicroRNAs (miRNAs) play a key role in the regulation of the transcriptome and have been identified as a key mediator in human disease and drug response. However, even if miRNA expression can be precisely detected, the information regarding miRNAs action on a particular part of the transcriptome is still lacking. Here, we introduced a novel concept, the Context-specific MiRNA activity (CoMi activity), to reflect a miRNA's regulation effect on a context specific gene set, by calculating the statistical difference between the distributions of its target gene expression and non-target gene expression. In this study we investigate whether CoMi activity could provide a novel perspective on miRNA mechanisms of action in disease and drug response, and facilitate in silico drug screening. Results: Using breast cancer as an example, we examined the CoMi activity based on a Gene Ontology (GO) term as context. Then we constructed a differential CoMi activity network (cancer vs. normal), based on the comi activity represents as a link between miRNAs and GO terms. (e.g. hsa-miR-27a's regulation on GO term "apoptosis"). The topological analysis of the generated network demonstrated that the cancer specific CoMi network is a scale free network. The highly connected nodes highlighted a group of known onco-miRNAs (e.g. hsamiR- 183*) and tumor suppressor miRNAs (e.g. hsa-miR-34a), as well as some well-known cancer related GO biological processes (e.g. apoptosis). Interestingly, we found that chemotherapeutic drug treatment can counteract the disregulated CoMi activity in the cancer-specific network. For instance, 100% of down-regulated CoMi activities in a "core" breast cancer network contains apoptosis-related GO terms that could be counteracted by Paclitaxel treatment. To perform in silico drug screening, the similarity of a query CoMi activity signature (e.g. differential CoMi activity in cancer vs. normal) to each of the reference CoMi activities (converted from reference mRNAs expression profiles in the Connectivity Map) was assessed. We found that the most negatively correlated compounds significantly overlapped with known cancer drugs. Conclusions: By defining a Stability Index for in silico drug screening, we found CoMi activity signatures strikingly outperformed the traditional CMAP method or mRNA-based signatures. Thus, the dynamic remodeling of context-specific miRNAs regulation network could reveal the hidden miRNAs that act as key mediators of drug action and facilitate in silico cancer drug screening. © 2011 IEEE.

Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks.

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Network-based Identification of Micrornas As Potential Pharmacogenomic Biomarkers for Anticancer Drugs

Dynamic remodeling of context-specific miRNAs regulation networks facilitate in silico cancer drug screening

Context-specific miRNA regulation network predicts cancer prognosis

Identification of Mirna Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response

Identification of Chemoresistance-Associated Mirnas in Breast Cancer

Identification of biomarker microRNAs for predicting the response of colorectal cancer to neoadjuvant chemoradiotherapy based on microRNA regulatory network

A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer

Accurate Prediction And Elucidation Of Drug Resistance Based On The Robust And Reproducible Chemoresponse Communities

Genome-wide Profiles of Methylation, Micrornas, and Gene Expression in Chemoresistant Breast Cancer

A MicroRNA Expression Signature in Taxane-anthracycline-based Neoadjuvant Chemotherapy Response

Use of an RNA Interference Screen-Derived Mitotic and Ceramide Pathway Metagene to Predict Response to Paclitaxel Combination Chemotherapy in Primary Breast Cancer.

A Metabolomics Approach for Predicting the Response to Neoadjuvant Chemotherapy in Cervical Cancer Patients

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

Consistent Principal Components from Triple Negative Breast Cancer Expression Profiles Yields Agent Specific Predictors of Chemotherapy Response.

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response

Predicting Potential Drugs for Breast Cancer Based on Mirna and Tissue Specificity

Predicting Breast Cancer Chemotherapeutic Response Using a Novel Tool for Microarray Data Analysis.